Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Under 12

 

• Takeda Pharmaceutical Co Ltd 
  TAK+0.43%+ Free Alerts
   announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
• The data demonstrated positive results of Takhzyro (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients.
• HAE attacks, which can involve serious and severely debilitating swelling in the abdomen, face, feet, genitals, hands, and throat, may occur very early in childhood. 
• Takhzyro reduced the rate of HAE attacks in children by a mean of 94.8% compared to baseline, from 1.84 attacks per month to 0.08 attacks during treatment.
• Most patients (76.2%) were attack-free during the 52-week treatment period, with an average of 99.5% attack-free days.
• No deaths or serious treatment-emergent adverse events (TEAEs) were reported during the study, and no patients withdrew from the study due to TEAEs.

https://www.benzinga.com/general/biotech/22/07/27932268/takedas-hereditary-angioedema-treatment-prevents-attacks-in-kids-below-12-years